Terms and Agreement
Please agree to the terms to continue using the chat feature.
GenEmbryomics is the first company in the world to offer a comprehensive whole-genome sequencing screening test for in vitro fertilization (IVF) embryos, providing a novel way to screen for genetic diseases before pregnancy. De novo mutations spontaneously occurring at fertilization account for over 4,525 genetic diseases that are routinely missed by currently used preimplantation genetic testing.
GenEmbryomics has developed the world’s first genetic screening for IVF capable of screening for more than 4,500 genetic conditions. GenEmbryomics innovative screening solution is comparatively priced to current testing solutions which have limited screening capabilities.
The Company is employing a B2B business model targeting IVF clinics globally. Initial commercialization plans are focused on the US, Europe, and Middle East, leveraging the key opinion leader status of the Company’s Executive Director and Senior Advisor, Dr. Santiago Munné. Dr. Munné developed the first Preimplantation Genetic Diagnosis (PGD) test to detect embryonic numerical chromosome abnormalities to avoid Down’s syndrome and other abnormalities and is extremely well-known amongst clinic owners.
Globally, the IVF market was estimated at $16.9 billion in 2018 and is expected to grow to $36.4 billion in 2026, a compound annual growth rate of 10.1%. GenEmbryomics is ideally positioned to capitalize on this demand, creating a compelling opportunity for early investors.
Red Chat is here to summarize the SEC filing data on GENEMBRYOMICS
Please agree to the terms to continue using the chat feature.